← Leaderboards
Jaroslaw P Maciejewski
Cleveland Clinic Lerner Com-Cwru
$28,244,801
Attributed
$34,940,412
Total exposure
22
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,289,352 · 23
By mechanism
R01$21,400,244 · 12
U54$9,778,270 · 6
R35$5,720,314 · 1
C06$2,039,261 · 1
K24$1,163,578 · 1
P30$159,685 · 1
Top collaborators
- Richard A Padgett13 shared
- Babal K Jha9 shared
- Eckhard Jankowsky4 shared
- Li Lily Wang1 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- James Matthew Hiznay$128,703
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingDysmyelopoietic SyndromesBaseMolecularCellsHematopoiesisImmuneGenomicsEvolutionLesionPathogenesisProductionStem CellsGenesAffectMutationHematopoieticDefectLeadPathway InteractionsDiagnosticTechnologyLeukemiaSomatic Mutation
Grant awards (82)
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$658,812
R01 · FY2025 · DK · contact PI
Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia$654,837
R01 · FY2025 · CA
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$608,324
R01 · FY2025 · CA · contact PI
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$632,461
R01 · FY2024 · DK · contact PI
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$577,908
R01 · FY2024 · CA · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$951,000
R35 · FY2023 · HL · contact PI
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$658,812
R01 · FY2023 · DK · contact PI
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$596,157
R01 · FY2023 · CA · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$122,674
R35 · FY2023 · HL · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$951,000
R35 · FY2022 · HL · contact PI
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$658,812
R01 · FY2022 · DK · contact PI
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$596,157
R01 · FY2022 · CA · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$40,891
R35 · FY2022 · HL · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$951,000
R35 · FY2021 · HL · contact PI
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$608,324
R01 · FY2021 · CA · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$951,000
R35 · FY2020 · HL · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$764,024
R35 · FY2019 · HL · contact PI
Novel Spliceosomal Defects in Myelodysplastic Syndromes$608,289
R01 · FY2019 · HL · contact PI
Hematopoietic and Immune Cancer Biology Research Program$74,237
P30 · FY2019 · CA · contact PI
Novel Spliceosomal Defects in Myelodysplastic Syndromes$608,289
R01 · FY2018 · HL · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$592,475
R35 · FY2018 · HL · contact PI
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2018 · HL · contact PI
Hematopoietic and Immune Cancer Biology Research Program$76,190
P30 · FY2018 · CA · contact PI
Hematopoietic and Immune Cancer Biology Research Program$9,258
P30 · FY2018 · CA · contact PI
Novel Spliceosomal Defects in Myelodysplastic Syndromes$608,289
R01 · FY2017 · HL · contact PI
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2017 · HL · contact PI
Therapeutic Implications of Molecular Defects in Bone Marrow Failure$396,250
R35 · FY2017 · HL · contact PI
Investigations of Consequences of U2AF1 Mutations in MDS$396,250
R01 · FY2017 · HL · contact PI
Novel Spliceosomal Defects in Myelodysplastic Syndromes$622,914
R01 · FY2016 · HL · contact PI
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2016 · HL · contact PI
The Role of Somatic Mutations in Aplastic Anemia$396,250
R01 · FY2016 · HL · contact PI
Investigations of Consequences of U2AF1 Mutations in MDS$396,250
R01 · FY2016 · HL · contact PI
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2015 · HL · contact PI
The Role of Somatic Mutations in Aplastic Anemia$396,250
R01 · FY2015 · HL · contact PI
Investigations of Consequences of U2AF1 Mutations in MDS$390,306
R01 · FY2015 · HL · contact PI
Investigations of Consequences of U2AF1 Mutations in MDS$388,325
R01 · FY2014 · HL · contact PI
Training/Research Center-Bone Marrow Failure Syndromes$134,301
K24 · FY2014 · HL · contact PI
Investigations of Consequences of U2AF1 Mutations in MDS$376,933
R01 · FY2013 · HL · contact PI
Molecular Pathogenesis of MDS and CMML$373,660
R01 · FY2013 · HL · contact PI
Viral Pathogenesis of Idiopathic Bone Marrow Failure and Immune Cytopenias$373,148
R01 · FY2013 · AI · contact PI
Training/Research Center-Bone Marrow Failure Syndromes$134,301
K24 · FY2013 · HL · contact PI
Molecular Pathogenesis of MDS and CMML$392,500
R01 · FY2012 · HL · contact PI
Viral Pathogenesis of Idiopathic Bone Marrow Failure and Immune Cytopenias$384,689
R01 · FY2012 · AI · contact PI
Training/Research Center-Bone Marrow Failure Syndromes$134,301
K24 · FY2012 · HL · contact PI
Molecular Pathogenesis of MDS and CMML$392,500
R01 · FY2011 · HL · contact PI
Viral Pathogenesis of Idiopathic Bone Marrow Failure and Immune Cytopenias$384,689
R01 · FY2011 · AI · contact PI
Training/Research Center-Bone Marrow Failure Syndromes$134,301
K24 · FY2011 · HL · contact PI
Translational Hematology and Oncology Research Laboratory Expansion Project$2,039,261
C06 · FY2010 · RR · contact PI
Molecular Pathogenesis of MDS and CMML$392,500
R01 · FY2010 · HL · contact PI
Viral Pathogenesis of Idiopathic Bone Marrow Failure and Immune Cytopenias$388,575
R01 · FY2010 · AI · contact PI
Training/Research Center-Bone Marrow Failure Syndromes$134,301
K24 · FY2010 · HL · contact PI
Viral Pathogenesis of Idiopathic Bone Marrow Failure and Immune Cytopenias$392,500
R01 · FY2009 · AI · contact PI
TCR Diagnostics in LGL Leukemia and Immune Cytopenias$286,517
R01 · FY2009 · CA · contact PI
Training/Research Center--Bone Marrow Failure Syndromes$98,777
K24 · FY2009 · HL · contact PI
Bone Marrow Failure Clinical Research Center$832,818
U54 · FY2008 · RR · contact PI
BONE MARROW FAILURE CLINICAL RESEARCH CENTER$832,818
U54 · FY2008 · RR · contact PI
Predisposition to chromosomal alterations in MDS$366,235
R01 · FY2008 · HL · contact PI
TCR Diagnostics in LGL Leukemia and Immune Cytopenias$286,517
R01 · FY2008 · CA · contact PI
Training/Research Center--Bone Marrow Failure Syndromes$98,774
K24 · FY2008 · HL · contact PI
BONE MARROW FAILURE CLINICAL RESEARCH CENTER$404,786
U54 · FY2007 · RR · contact PI
Bone Marrow Failure Clinical Research Center$404,786
U54 · FY2007 · RR · contact PI
Predisposition to chromosomal alterations in MDS$366,235
R01 · FY2007 · HL · contact PI
Molecular T Cell Repertoire in Aplastic Anemia$362,679
R01 · FY2007 · HL · contact PI
TCR Diagnostics in LGL Leukemia and Immune Cytopenias$286,517
R01 · FY2007 · CA · contact PI
Training/Research Center--Bone Marrow Failure Syndromes$98,772
K24 · FY2007 · HL · contact PI
Bone Marrow Failure Clinical Research Center$977,392
U54 · FY2006 · RR · contact PI
BONE MARROW FAILURE CLINICAL RESEARCH CENTER$977,392
U54 · FY2006 · RR · contact PI
Predisposition to chromosomal alterations in MDS$377,173
R01 · FY2006 · HL · contact PI
Molecular T Cell Repertoire in Aplastic Anemia$373,511
R01 · FY2006 · HL · contact PI
TCR Diagnostics in LGL Leukemia and Immune Cytopenias$295,074
R01 · FY2006 · CA · contact PI
Training/Research Center--Bone Marrow Failure Syndromes$98,774
K24 · FY2006 · HL · contact PI
BONE MARROW FAILURE CLINICAL RESEARCH CENTER$1,124,410
U54 · FY2005 · RR
Bone Marrow Failure Clinical Research Center$1,124,410
U54 · FY2005 · RR
Molecular T Cell Repertoire in Aplastic Anemia$382,500
R01 · FY2005 · HL
Predisposition to chromosomal alterations in MDS$374,759
R01 · FY2005 · HL
TCR Diagnostics in LGL Leukemia and Immune Cytopenias$297,737
R01 · FY2005 · CA
Training/Research Center--Bone Marrow Failure Syndromes$96,976
K24 · FY2005 · HL
BONE MARROW FAILURE CLINICAL RESEARCH CENTER$1,089,924
U54 · FY2004 · RR
Bone Marrow Failure Clinical Research Center$1,089,924
U54 · FY2004 · RR
Molecular T Cell Repertoire in Aplastic Anemia$372,500
R01 · FY2004 · HL
Bone Marrow Failure Scientific Symposium$28,000
R13 · FY2004 · HL
Bone Marrow Failure Clinical Research Center$919,610
U54 · FY2003 · RR